TY - JOUR
T1 - Competitive athletes with implantable cardioverter–defibrillators—How to program? Data from the Implantable Cardioverter–Defibrillator Sports Registry
AU - Olshansky, Brian
AU - Atteya, Gourg
AU - Cannom, David
AU - Heidbuchel, Hein
AU - Saarel, Elizabeth V.
AU - Anfinsen, Ole Gunnar
AU - Cheng, Alan
AU - Gold, Michael R.
AU - Müssigbrodt, Andreas
AU - Patton, Kristen K.
AU - Saxon, Leslie A.
AU - Wilkoff, Bruce L.
AU - Willems, Rik
AU - Dziura, James
AU - Li, Fangyong
AU - Brandt, Cynthia
AU - Simone, Laura
AU - Wilhelm, Matthias
AU - Lampert, Rachel
N1 - Funding Information:
Research funded by Medtronic , St. Jude , and Boston Scientific . Dr Olshansky: Lundbeck, Speakers Bureau; Boehringer Ingelheim, Consultant/Advisory Board; Lundbeck, Consultant/Advisory Board; Amarin, Consultant/Advisory Board. Dr Atteya: None. Dr Cannom: Medtronic, Speakers Bureau; Boston Scientific, Speakers Bureau; Sanofi, Speakers Bureau; St. Jude, Speakers Bureau; Medtronic, Consultant/Advisory Board; Boston Scientific, Consultant/Advisory Board. Dr Heidbuchel: Biotronik, Research Grant; Boston Scientific, Research Grant; Boehringer Ingelheim, Consultant/Advisory Board; Daiichi Sankyo, Consultant/Advisory Board; Pfizer, Consultant/Advisory Board; Merck, Consultant/Advisory Board; Bayer, Consultant/Advisory Board. Dr Saarel: None. Dr Anfinsen: None. Dr Cheng: Medtronic, Employment. Dr Gold: Boston Scientific and Medtronic, Consultant and Clinical Trials. Dr Müssigbrodt: None. Dr Patton: None. Dr Saxon: None. Dr Wilkoff: Convatech, Speakers Bureau; Medtronic, Consultant/Advisory Board; St. Jude Medical/Abbott, Consultant/Advisory Board; Spectranetics, Consultant/Advisory Board. Dr Willems: Flanders, Research Grant; Biotronik, Research Grant; Boston Scientific Belgium, Research Grant; Medtronic Belgium, Research Grant; Medtronic, Consultant/Advisory Board; Boston Scientific, Consultant/Advisory Board; Biotronik, Consultant/Advisory Board; St. Jude Medical, Consultant/Advisory Board; Sorin, Consultant/Advisory Board. Dr Matthias: None. Dr Lampert: Medtronic, Research Grant; St. Jude Medical, Research Grant; Boston Scientific, Research Grant; Medtronic, Consultant/Advisory Board.
Publisher Copyright:
© 2018 Heart Rhythm Society
PY - 2019/4
Y1 - 2019/4
N2 - Background: Athletes with an implantable cardioverter–defibrillator (ICD) may require unique optimal device-based tachycardia programming. Objective: The purpose of this study was to assess the association of tachycardia programming characteristics of ICDs with occurrence of shocks, transient loss-of-consciousness, and death among athletes. Methods: A subanalysis of a prospective, observational, international registry of 440 athletes with ICDs followed for a median of 44 months was performed. Programming characteristics were divided into groups for rate cutoff (very high, high, or low) and detection (long-detection interval [>nominal] or nominal). Endpoints included total, appropriate, and inappropriate shocks, transient loss-of-consciousness, and mortality. Results: In this cohort, 62% were programmed with high-rate cutoff and 30% with long detection. No athlete died of an arrhythmia (related or unrelated) to ICD shocks. Three patients had sustained ventricular tachycardia below programmed detection rate, presenting as palpations and/or dizziness. ICD shocks were received by 98 athletes (64 appropriate, 32 inappropriate); 2 patients received both. Programming a high-rate cutoff was associated with decreased risk of total (P =.01) and inappropriate (P =.04) shocks overall and during competition or practice. Programming long-detection intervals was associated with fewer total shocks. Single- vs dual-chamber devices and the number of zones were unrelated to risk of shock. Transient loss-of-consciousness, associated with 27 appropriate shocks, was not related to programming characteristics. Conclusion: High-rate cutoff and long-detection duration programming of ICDs in athletes at risk for sudden death can reduce total and inappropriate ICD shocks without affecting survival or the incidence of transient loss-of-consciousness.
AB - Background: Athletes with an implantable cardioverter–defibrillator (ICD) may require unique optimal device-based tachycardia programming. Objective: The purpose of this study was to assess the association of tachycardia programming characteristics of ICDs with occurrence of shocks, transient loss-of-consciousness, and death among athletes. Methods: A subanalysis of a prospective, observational, international registry of 440 athletes with ICDs followed for a median of 44 months was performed. Programming characteristics were divided into groups for rate cutoff (very high, high, or low) and detection (long-detection interval [>nominal] or nominal). Endpoints included total, appropriate, and inappropriate shocks, transient loss-of-consciousness, and mortality. Results: In this cohort, 62% were programmed with high-rate cutoff and 30% with long detection. No athlete died of an arrhythmia (related or unrelated) to ICD shocks. Three patients had sustained ventricular tachycardia below programmed detection rate, presenting as palpations and/or dizziness. ICD shocks were received by 98 athletes (64 appropriate, 32 inappropriate); 2 patients received both. Programming a high-rate cutoff was associated with decreased risk of total (P =.01) and inappropriate (P =.04) shocks overall and during competition or practice. Programming long-detection intervals was associated with fewer total shocks. Single- vs dual-chamber devices and the number of zones were unrelated to risk of shock. Transient loss-of-consciousness, associated with 27 appropriate shocks, was not related to programming characteristics. Conclusion: High-rate cutoff and long-detection duration programming of ICDs in athletes at risk for sudden death can reduce total and inappropriate ICD shocks without affecting survival or the incidence of transient loss-of-consciousness.
KW - Athletes
KW - Cardiac arrest
KW - Implantable cardioverter–defibrillator
KW - Implantable cardioverter–defibrillator programming
KW - Sports participation
KW - Ventricular fibrillation
KW - Ventricular tachycardia
UR - http://www.scopus.com/inward/record.url?scp=85063050878&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85063050878&partnerID=8YFLogxK
U2 - 10.1016/j.hrthm.2018.10.032
DO - 10.1016/j.hrthm.2018.10.032
M3 - Article
C2 - 30389442
AN - SCOPUS:85063050878
SN - 1547-5271
VL - 16
SP - 581
EP - 587
JO - Heart Rhythm
JF - Heart Rhythm
IS - 4
ER -